Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other trea... Author: BeaconMedIC Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement ... Author: BeaconMedIC Added: 07/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2018 Category: Cancer & Oncology Source Type: podcasts

What is the Role of Bevacizumab in Stage IV NSCLC_ [720p]
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC. Author: cancergrace Added: 05/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 16, 2018 Category: Cancer & Oncology Source Type: podcasts

IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this i... Author: VJOncology Added: 04/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab & Olapanib
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab... Author: Cancer-News Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib at Kidney Cancer Association 2017 in... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivoluma... Author: moasc Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD... Author: Genitourinary-Cancer-Meeting Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Squamous Cell Carcinoma 4+ EGFR Carboplatin Cetuximab Safely or Bevacizumab
Roy S. Herbst, MD, PhD of Yale Cancer Center discusses squamous cell carcinoma 4+ EGFR and giving carboplatin cetuximab safely or bevacizumab. From the 22nd Annual Perspectives in Thoracic Oncology i... Author: thoraciconcology Added: 01/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 4, 2018 Category: Cancer & Oncology Source Type: podcasts

T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021)
Dr. Jack West reviews provocative biomarker results on the IMpower150 trial that tested atezolizumab with carboplatin/paclitaxel +/- bevacizumab & revealed strongest benefit of atezo in those with... Author: BeaconMedIC Added: 12/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 22, 2017 Category: Cancer & Oncology Source Type: podcasts

Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients ... Author: BeaconMedIC Added: 12/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2017 Category: Cancer & Oncology Source Type: podcasts

IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma
Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevac... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial in mccRCC
Discussion of Correlatives Associated with Presurgical Nivolumab + - Bevacizumab or Ipilimumab Trial i... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

Correlatives Associated with Bevacizumab/Atezolizumab
Walter Stadler, MD of The University of Chicago discusses the Correlatives Associated with Bevacizumab/Atezolizumab at the annual 2017 Kidney Cancer Association symposium in Miami, FL Author: kidneycancer Added: 11/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-t... Author: imedex Added: 10/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 13, 2017 Category: Cancer & Oncology Source Type: podcasts

Final Results of the TAVAREC Trial: Temozolomide with or without Bevacizumab in Glioma
Daniela Bota, MD of UC Irvine Health gives an overview of the final results of the TAVAREC trial, which studied temozolomide and bevacizumab in patients with glioma. This was recorded at the 2017 MOAS... Author: moasc Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts

AvaALL: Bevacizumab Beyond Progression in Patients with Metastatic Non-Squamous NSCLC
Viola Zhu, MD, PhD of UC Irvine Health discusses the AvaALL trial and the use of bevacizumab beyond progression in patients with non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlig... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Use of Atezolizumab, Bevacizumab, and Sunitinib in Kidney Cancer
Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in kidney cancer research specifically a phase II study on the use of Atezolizumab and Bevacizumab for patients with locally advanced... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane review of these drugs and used a network meta-analysis to compare their effects. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts

Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane Review of these drugs and used a network meta-analysis to compare their effects. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts

Anti-vascular endothelial growth factor (anti-VEGF) drugs for diabetic macular oedema
Diabetic macular oedema is a common complication of diabetes, in which damage to the blood vessels at the back of the eye leads to swelling. Lucentis, Eylea and Avastin are three antiangiogenic drugs that can be injected into the eye to treat the blood vessels and reduce the swelling. In June 2017, Gianni Virgili from the University of Florence in Italy, and colleagues, updated their Cochrane Review of these drugs and used a network meta-analysis to compare their effects.Note:  The latest version of this review has been published on October 2018 but the conclusions as outlined in this podcast have not changed. (Source...
Source: Podcasts from The Cochrane Library - July 12, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts

A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
David McDermott, MD of Dana-Farber Cancer Center discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients at the 12... Author: kidneycancer Added: 04/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 26, 2017 Category: Cancer & Oncology Source Type: podcasts

Ovarian Cancer Treatment Trends for 2017 Includes Chemotherapy, PARP Inhibitors, and Bevacizumab
Don Dizon, MD of Massachusetts General Hospital gives an overview of the treatment trends for 2017 in ovarian cancer treatment, which were discussed at the 2017 Society of Gynecologic Oncology (SGO)s... Author: SGO2017 Added: 03/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2017 Category: Cancer & Oncology Source Type: podcasts

Cul es el rol de Avastin (bevacizumab) en el tratamiento del cncer de pulmn de clulas no pequeas en la actualidad?
What is the role of Avastin (bevacizumab) in treating advanced NSCLC today? Author: cancergrace Added: 12/07/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 7, 2016 Category: Cancer & Oncology Source Type: podcasts

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care
Thomas Hutson, Memorial Sloan Kettering Cancer Center, New York, NY presents A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRC... Author: kidneycancer Added: 11/07/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2016 Category: Cancer & Oncology Source Type: podcasts

Bevacizumab in combination with chemotherapy in metastatic urothelial cancer
Dr. Arjun Balar, MD of NYU Langone Medical Center discusses Bevacizumab in combination with chemotherapy in metastatic urothelial cancer at ASCO 2016 Author: ASCO2016 Added: 06/16/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 16, 2016 Category: Cancer & Oncology Source Type: podcasts

What is the Role of Bevacizumab in Stage IV NSCLC?
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC. http://cancergrace.org/lung...... Author: cancergrace Added: 04/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2016 Category: Cancer & Oncology Source Type: podcasts

Olaparib and bevacizumab: On the horizon for treating ovarian cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS(Mysore), MObGyn(Mal), FRCOG(Lond), FRCP(Ire), AM... Author: EMJ Added: 02/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 18, 2016 Category: Cancer & Oncology Source Type: podcasts

FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 20... Author: ASCOGI2016 Added: 01/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2016 Category: Cancer & Oncology Source Type: podcasts

ASCO GI 2016: FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab
Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab at ASCO GI 2016 Author: ASCOGI2016 Added: 01/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2016 Category: Cancer & Oncology Source Type: podcasts

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer | Dr Eric Pujade-Lauraine at ECC 2015
At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, random... Author: EMJ Added: 11/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2015 Category: Cancer & Oncology Source Type: podcasts

BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer | Dr Bartomeu Massuti at ECC 2015
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Pl... Author: EMJ Added: 11/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 16, 2015 Category: Cancer & Oncology Source Type: podcasts

Opening the Floodgates to T Cells – Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC
Jeffrey Wallin, Ph.D. of Genentech presents "Opening the Floodgates to T Cells – Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC" at the 14th International Kidney Cance... Author: kidneycancer Added: 11/07/2015 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2015 Category: Cancer & Oncology Source Type: podcasts

The Survival Benefit with Avastin Added to Chemotherapy
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimt... Author: cancergrace Added: 10/31/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 31, 2015 Category: Cancer & Oncology Source Type: podcasts

ECOG 1505 Study: No Benefit of Post-Operative Avastin in Early Stage Lung Cancer Patients
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early sta... Author: cancergrace Added: 10/30/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2015 Category: Cancer & Oncology Source Type: podcasts

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mut... Author: cancergrace Added: 10/07/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 7, 2015 Category: Cancer & Oncology Source Type: podcasts

Sunitinib v. PD-L1 with Bevacizumab
Nicholas J. Vogelzang, MD of the University of Illinois discusses a new trial Sunitinib v. PD-L1 with Bevacizumab Author: cancergiants Added: 06/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 17, 2015 Category: Cancer & Oncology Source Type: podcasts

Bevacizumab in conjunction with Pembrolizumab for Treatment of Metastatic Kidney Cancer
Arkadiusz Dudek, MD, PhD, of the University of Illinois Cancer Center, Sponsor investigator, discusses a Big Ten Cancer Research Consortium trial combining the antibody MK-3475 (pembrolizumab) with be... Author: BigTenCRC Added: 06/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 17, 2015 Category: Cancer & Oncology Source Type: podcasts

Use of Bevacizumab in Lung Cancer
The use of bevacizumab in wild-type and EGFR-mutation positive lung cancer. Mark Socinski, MD Author: onclivetv Added: 03/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 16, 2015 Category: Cancer & Oncology Source Type: podcasts

Refractive Outcomes After Bevacizumab Monotherapy (JAMA Ophthalmology)
Interview with Helen A. Mintz-Hittner, MD, author of Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - November 13, 2014 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts

Bevacizumab's Role in Late-Stage Cervical Cancer
Dr. Maurie Markman discusses the recent FDA approval of bevacizumab for recurrent or late-stage cervical cancer and weighs the benefits of the drug in this setting against its toxicity profile. (Source: Medscape Oncology)
Source: Medscape Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

ASCO 2014 - Miller - Bevacizumab in the adjuvant treatment of HER2 negative breast cancer
For more free video updates go to www.oncologyeducation.com... Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not improve IDFS or OS in pts with high risk HER2- breas... Author: oncologyeducation Added: 07/30/2014 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2014 Category: Cancer & Oncology Source Type: podcasts

Dr. Monk on Bevacizumab in Recurrent Cervical Cancer
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer. Author: onclivetv Added: 07/16/2014 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2014 Category: Cancer & Oncology Source Type: podcasts

Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
http://cancerGRACE.org/... Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGF... Author: cancergrace Added: 06/16/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 16, 2014 Category: Cancer & Oncology Source Type: podcasts

ECOG1505: Will Avastin Be Treatment for Early Stage Lung Cancer Patients?
http://cancerGRACE.org/... Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. Fe... Author: cancergrace Added: 05/20/2014 (Source: Oncology Tube)
Source: Oncology Tube - May 20, 2014 Category: Cancer & Oncology Source Type: podcasts

Why has everything beyond bevacizumab failed in angiogenesis inhibition?
Dr. Corey Langer chairs this 18th Annual "Perspectives in Thoracic Oncology" meeting which is captured in its entirety in this webcast. An expert faculty covers every aspect of lung cancer m... Author: imedex Added: 01/24/2014 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2014 Category: Cancer & Oncology Source Type: podcasts

New Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - January 17, 2014 Category: Gastroenterology Authors: Medscape Source Type: podcasts

New Regimen for Elderly Patients With mCRC
Dr. David Kerr reports on a study in which bevacizumab/capecitabine significantly improved PFS in patients at least 70 years old with advanced colorectal cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

ICON7 Trial Update - Dr. Amit Oza
For more updates visit www.oncologyeducation.com.... Dr. Amit Oza with an update from ECC 2013 on the final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with... Author: oncologyeducation Added: 10/09/2013 (Source: Oncology Tube)
Source: Oncology Tube - October 9, 2013 Category: Cancer & Oncology Source Type: podcasts

Bevacizumab: Mixed Results in Glioblastoma
Prof. Wolfgang Wick reviews the neuro-oncology highlights from ECC 2013, focusing on glioblastoma and mixed results of bevacizumab trials. (Source: Medscape Oncology)
Source: Medscape Oncology - October 8, 2013 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts